UNSPSC 51182017: Androstanolone or dht or dihydrotestosterone

This classification denotes an anabolic steroid with the molecular formula C19H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08J2K08A3Y, chemically known as 4,5alpha-dihydrotestosterone but generally known as androstanolone, which bears US NIH Compound Identifier 10635. European Medicines Agency schedules Androstanolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05509MIG.

UNSPSC 51182017 Androstanolone or DHT or dihydrotestosterone is a Commodity code under which state and local governments procure specific active pharmaceutical ingredients and hormone-based pharmaceutical products for distribution through authorized wholesaler networks to state and local government facilities. The scope of work centers on manufacturers supplying identified pharmaceutical products with specified National Drug Codes, detailed product information including NDC codes, SKUs, UPCs, generic descriptions, strength, dosage forms, trade names, packaging configurations, and manufacturing locations. State and local procurement under this code involves multi-state cooperative purchasing alliances and state pharmacy and medicinal supply programs that manage pharmaceutical inventory for institutional customers. Vendors must certify compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements, maintain contractual relationships with authorized pharmaceutical wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and demonstrate pricing flexibility through multiple price structures such as flat price, net price formats, or WAC-minus pricing.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other MMCAP member states. The solicitation (S1070000015802) closes March 26, 2026, with awarded vendors to be provided to authorized wholesalers by May 15, 2026 and resulting agreements effective July 1, 2026. MMCAP evaluation weights pricing competitiveness at 75 percent, with smaller weights on fixed pricing (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain comprehensive insurance coverage including $5,000,000 commercial general liability per occurrence and $2,000,000 network security and privacy liability, and the contract term is two years for new responders with optional extensions, or alignment with existing expiration dates through June 30, 2028 for incumbent responders.